Literature DB >> 9402038

Caffeine induces central cholinergic analgesia.

C Ghelardini1, N Galeotti, A Bartolini.   

Abstract

The antinociceptive effect of caffeine was examined by using the hot-plate, abdominal constriction tests in mice and the tail flick and paw-pressure tests in rats. Caffeine (1-5 mg kg-1 s.c. in mice; 2.5-5 mg kg-1 i.p. in rats) produced significant antinociception in both species which was prevented by atropine (5 mg kg-1 i.p.), pirenzepine (0.1 microgram per mouse i.c.v.), hemicholinium-3 (1 microgram/ mouse i.c.v.) and N6-cyclopentyladenosine (5 micrograms/mouse i.c.v.), but not by naloxone (1 mg kg-1 i.p.), CGP 35348 (100 mg kg-1 i.p.), alpha-methyl p-tyrosine (100 mg kg-1 i.p.) and reserpine (2 mg kg-1 i.p.). Intracerebroventricular injection of caffeine in mice at doses (2.5-5 micrograms per mouse) which were largely ineffective by parenteral routes, induces an antinociception whose intensity equalled that obtainable s.c. or i.p. In the antinociceptive dose-range, caffeine did not produce any behavioural impairment as revealed by the rotarod and Irwing tests. On the basis of the above data, it can be postulated that caffeine exerts an antinociceptive effect mediated by central amplification of cholinergic transmission.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9402038     DOI: 10.1007/pl00005094

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  12 in total

Review 1.  Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache.

Authors:  Sheridan M Hoy; Lesley J Scott
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

2.  A Preliminary Study on the Effects of Self-Reported Dietary Caffeine on Pain Experience and Postoperative Analgesia.

Authors:  Nirmani P Karunathilake; Reginald F Frye; Mary F Stavropoulos; Mary A Herman; Barbara A Hastie
Journal:  J Caffeine Res       Date:  2012-12

Review 3.  Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?

Authors:  Andreas Straube; Bernhard Aicher; Bernd L Fiebich; Gunther Haag
Journal:  BMC Neurol       Date:  2011-03-31       Impact factor: 2.474

Review 4.  A benefit-risk assessment of caffeine as an analgesic adjuvant.

Authors:  W Y Zhang
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Hyperalgesia, low-anxiety, and impairment of avoidance learning in neonatal caffeine-treated rats.

Authors:  Hong-Zhen Pan; Hwei-Hsien Chen
Journal:  Psychopharmacology (Berl)       Date:  2006-11-10       Impact factor: 4.530

Review 6.  Caffeine and headaches.

Authors:  Robert E Shapiro
Journal:  Curr Pain Headache Rep       Date:  2008-08

7.  The central analgesia induced by antimigraine drugs is independent from Gi proteins: superiority of a fixed combination of indomethacin, prochlorperazine and caffeine, compared to sumatriptan, in an in vivo model.

Authors:  Carla Ghelardini; Nicoletta Galeotti; Elisa Vivoli; Irene Grazioli; Carla Uslenghi
Journal:  J Headache Pain       Date:  2009-09-15       Impact factor: 7.277

Review 8.  Post-dural puncture headaches in children. A literature review.

Authors:  Elke Janssens; Peter Aerssens; Phillipe Alliët; Phillipe Gillis; Marc Raes
Journal:  Eur J Pediatr       Date:  2003-01-15       Impact factor: 3.183

9.  Analgesic and antineuropathic drugs acting through central cholinergic mechanisms.

Authors:  Alessandro Bartolini; Lorenzo Di Cesare Mannelli; Carla Ghelardini
Journal:  Recent Pat CNS Drug Discov       Date:  2011-05-01

10.  Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study.

Authors:  G Sandrini; R Cerbo; E Del Bene; A Ferrari; S Genco; I Grazioli; P Martelletti; G Nappi; L Pinessi; P Sarchielli; P Tamburro; C Uslenghi; G Zanchin
Journal:  Int J Clin Pract       Date:  2007-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.